Información del artículo
El Texto completo está disponible en PDF
References
[1.]
L. Koutsky.
Epidemiology of genital human papillomavirus infection.
Am J Med, 102 (1997), pp. 3-8
[2.]
M.E. Hagensee, J.E. Cameron, J.E. Leigh, R.A. Clark.
Human papillomavirus infection and disease in HIV-infected individuals.
Am J Med Sci, 328 (2004), pp. 57-63
[3.]
R.E. Brown, J.G. Breugelmans, D. Theodo ratou, S. Benard.
Costs of detection and treatment of cervical cancer, cervi cal dysplasia and genital warts in the UK.
Curr Med Res Opin, 22 (2006), pp. 663-670
[4.]
C. O’Mahony.
Genital warts: current and future management options.
Am J Clin Dermatol, 6 (2005), pp. 239-243
[5.]
D. Calista.
Topical cidofovir for severe cutaneous human papillomavirus and molluscum contagiosum infections in patients with HIV/AIDS. A pilot study.
J Eur Acad Dermatol Venereol, 14 (2000), pp. 484-488
[6.]
D. Calista.
Regression of a cutaneous melanoma metastasis after intralesional cidofovir [letter].
Melanoma Res, 13 (2003), pp. 205-206
[7.]
D. Calista.
Topical 1% cidofovir for the treatment of basal cell carcinoma.
Eur J Dermatol, 12 (2002), pp. 562-564
[8.]
G. Andrei, R. Snoeck, J. Piette, P. Del venne, E. De Clercq.
Antiprolifera tive effects of acyclic nucleoside phosp honates on human papillomavirus (HPV)-harboring cell lines compared with HPV-negative cell lines.
Oncol Res, 10 (1998), pp. 523-531
[9.]
R. Snoeck, M. Bossens, D. Parent, B. Delaere, H. Degreef, M. Van Ranst, et al.
Phase II double-blind, placebo controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human papillomavirus infection.
Clin Infect Dis, 33 (2001), pp. 597-602
[10.]
J. Yan, S.L. Chen, H.N. Wang, T. Wu.
Meta-analysis of 5% imiquimod and 0.5% podophyllotoxin in the treat ment of condylomata acuminate.
Der matology, 213 (2006), pp. 218-223
Copyright © 2008. Academia Española de Dermatología y Venereología and Elsevier España, S.L.
